MedlinePlus: Infecciones por Helicobacter pylori

MedlinePlus: Infecciones por Helicobacter pylori
Source: NLM General Announcements - Category: Databases & Libraries Source Type: news

Related Links:

Source: Infection and Drug Resistance - Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
This study further evaluated the therapeutic potential and the mode of action underlying Cbf-K16 against clarithromycin- and amoxicillin-resistant H. pylori SS1. The MIC and MBC of Cbf-K16 against the tested H. pylori were 16 and 32 μg/ml, respectively, and its killing kinetics was time-dependent, reflecting the thorough elimination of drug-resistant bacteria within 24 h. This peptide also protected H. pylori-infected gastric epithelial cells (GES-1) from death by reducing the cell supernatant and intracellular bacterial counts by 1.9 and 2.9-log10 units, respectively. These data indicated the powerful antimicrobial...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
This study aimed to examine the influence of H. pylori eradication on serum PG, analyze its associated factors, and evaluate the long-term outcomes.Methods: H. pylori-positive patients who underwent gastroscopy and serum PG measurement were enrolled in a single academic hospital. After H. pylori eradication, the measurement of serum PG level was performed. Recovery of serum PG I/II ratio was defined as a PG I/II ratio after eradication of>3.0 in patients with a PG I/II ratio ≤ 3.0 before eradication. Follow-up involved serum PG measurement and gastroscopy with a rapid urease test annually.Results: In all, 327 patient...
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
In conclusion, the validated urea breath test and the stool antigen test are considered noninvasive practical approaches for the detection of H. pylori infection in Indonesia, with serological and urine tests as alternatives. PMID: 31693853 [PubMed - as supplied by publisher]
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Studies indicate that gastric cancer (GC) incidence has decreased, whereas signet ring cell carcinoma (SRC) incidence has increased. However, recent trends in GC incidence are unclear. We used our hospital can...
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Research article Source Type: research
Nigerian propolis: chemical composition, antioxidant activity and α-amylase and α-glucosidase inhibition. Nat Prod Res. 2019 Nov 08;:1-5 Authors: Alaribe CS, Esposito T, Sansone F, Sunday A, Pagano I, Piccinelli AL, Celano R, Cuesta Rubio O, Coker HA, Nabavi SM, Rastrelli L, Picerno P Abstract Propolis is an attractive natural ingredient to design health products due to its pharmacological effects. Our chemical investigation of a polar extract of Nigerian propolis (NP) led the isolation and identification of five isoflavonoids (1-4, 6), one diarylpropane (5) and one prenylated flavanone (7...
Source: Natural Product Research - Category: Biochemistry Authors: Tags: Nat Prod Res Source Type: research
Conclusions: Gastritis can cause changes in composition of fecal microbiome, which is exacerbated by H. pylori infection. These changes in gut microbiome may be related to drug resistance and development of chronic gastrointestinal diseases.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the“Company”), a specialty biopharmaceutical company primarily focused...
Source: - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Talicia combines omeprazole, amoxicillin, and rifabutin and is designed to address growing bacterial resistance to standard clarithromycin-based H pylori therapy.FDA Approvals
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Alert Source Type: news
RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Databases & Libraries | Helicobacter Pylori